Arabic Arabic English English French French German German
dark

GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform, announced it has entered into a sponsored research agreement (SRA) with Jeffrey S. Miller, M.D., Deputy Director of the University of Minnesota’s Masonic Cancer Center and Consulting Chief Scientific Officer of GT Biopharma. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Viewpoint Molecular Targeting(R) Partners with Industry Leader Pepscan to Accelerate Peptide Discovery Program

Next Post

Sobi to present data at the ISTH 2021 within rare haematology diseases

Related Posts
Total
0
Share